

MONDAY
APRIL 24 - 2006
8:00 – 11:30
PLENARY SESSIONS

**PS1 - INNOVATIONS IN CERVICAL CANCER PREVENTION: SCIENCE,
PRACTICE AND ACTIONS**

08:00 – 08:45

**PS1-1 - HPV DNA TESTING IN CERVICAL CANCER SCREENING: FROM
EVIDENCE TO POLICIES**

Chair : T. COX (USA)

J. CUZICK (UK)

- | | |
|---|--------------------------------|
| 1 – The US experience | T. WRIGHT (USA) |
| 2 – The European perspective | J. DILLNER (Sweden) |
| 3 – Application in developing countries | J. SELLORS (USA) |
| 4 – Consensus | T. COX (USA)
J. CUZICK (UK) |

08.45 - 09:30

PS1-2 -CURRENT KNOWLEDGE AND CLINICAL USE OF HPV GENOTYPING

Chairs: P. CASTLE (USA)

C. MEIJER (Netherlands)

- | | |
|--------------------|---|
| 1 –Research update | T. WRIGHT (USA) |
| 2 – Meta-analysis | E. MYERS (USA) |
| 3 – Consensus | P. CASTLE (USA)
C.MEIJER (Netherlands) |

09:30 – 10:15

PS1-3 - MOLECULAR MARKERS: HOW TO APPLY IN PRACTICE?

Chairs: M.Von KNEBEL DOEBERITZ (Germany)

K. SYRJÄNEN (Finland)

- | | |
|---|--|
| 1 - The role of viral expression in mRNA | J.DOORBAR (UK) |
| 2 - The value of P16 | M. von KNEBEL-DOEBERITZ(Germany) |
| 3 -Assessing the risk of disease and cost-effectiveness | E. MYERS (USA) |
| 4 - Future prospects | K. SYRJANEN (Finland)
M. von KNEBEL-DOEBERITZ (Germany) |

10:15-10:45-COFFEE BREAK

10:45 - 11:30

**PS1-4 - PREVENTION STRATEGIES OF CERVICAL CANCER IN HPV VACCINE
ERA: CHALLENGES FOR SUCCESS**

Chairs: D. HARPER (US)

X. BOSCH (Spain)

- | | |
|---|------------------------------------|
| 1 – Research update | J. SCHILLER (USA) |
| 2 – Impact access and public health issues | F. CUTTS (Switzerland) |
| 3 – New prevention strategies :screening versus vaccine | H. LAWSON (USA) |
| 4 – Recommendations for future development | D. HARPER (UK)
X. BOSCH (Spain) |